NCT07196774View on ClinicalTrials.gov

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

650

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Early-stage or Locally Advanced HER2-positive Breast Cancer
Interventions
DRUG

SHR-A1811 for Injection

SHR-A1811 for injection.

DRUG

Docetaxel injection

Docetaxel injection.

DRUG

Trastuzumab Injection

Trastuzumab injection.

DRUG

Carboplatin for Injection

Carboplatin for injection.

DRUG

Pertuzumab Injection

Pertuzumab injection.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY